HIGHER-RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGHER-RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGHER-RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Global race for better MDS treatment: can new drug combo extend lives?
Disease control Recruiting nowThis large, late-stage trial is testing if adding a new drug called lisaftoclax to the standard treatment (azacitidine) helps people with newly diagnosed high-risk MDS live longer. About 490 participants worldwide will be randomly assigned to receive either the new combination or…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
First patients to receive experimental drug for aggressive leukemia
Disease control Recruiting nowThis is the first-ever study in people for a new drug called GEN3018. It aims to find a safe and effective dose for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or is resistant to standard treatments. The main goals are to check the drug's safe…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called CCS1477 (inobrodib) in patients with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to check if the drug is safe, what side effects it causes, and if it shows signs of …
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC